SCHEMBL3367434

SCHEMBL3367434

Cc1cccc2nc(C(=O)Nc3ccccc3)cn12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.65
NPC1 O15118 4/20 0.65
GAA P10253 4/20 0.56
POLB P06746 1/20 0.54
KDM4E B2RXH2 2/20 0.54
MAPT P10636 2/20 0.54
LMNA P02545 2/20 0.54
RECQL P46063 1/20 0.54
BLM P54132 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
SMN1; SMN2 Q16637 5/20 0.51
ALDH1A1 P00352 1/20 0.51
ADORA2A P29274 2/20 0.49
ADORA1 P30542 2/20 0.49
AURKA O14965 1/20 0.48
RPS6KB1 P23443 1/20 0.48
CYP2C9 P11712 1/20 0.47
NR4A2 P43354 1/20 0.47
KMT2A Q03164 1/20 0.47
GLA P06280 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367951 0.82 RAB9A (0.56) RAB9ANPC1GAAPOLBLMNA
SCHEMBL31295474 0.81 GAA (0.63) RAB9ANPC1GAAPOLBKDM4E
SCHEMBL14793627 0.81 RAB9A (0.54) RAB9ANPC1GAAPOLBKDM4E
SCHEMBL15418819 0.81 RAB9A (0.61) RAB9ANPC1GAAPOLBKDM4E
SCHEMBL119926 0.81 GAA (0.66) RAB9ANPC1GAAPOLBKDM4E
SCHEMBL2489707 0.80 RAB9A (0.53) RAB9ANPC1GAAPOLBLMNA
SCHEMBL3367638 0.80 RAB9A (0.53) RAB9ANPC1GAAPOLBLMNA
SCHEMBL15419016 0.80 RAB9A (0.60) RAB9ANPC1GAAPOLBKDM4E
SCHEMBL3366002 0.80 RAB9A (0.53) RAB9ANPC1GAAPOLBLMNA
SCHEMBL4243991 0.78 GAA (0.59) RAB9ANPC1GAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP claimed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US claimed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US claimed
US-8404848-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI (FR) 2013-03-26 US disclosed
EP-2041133-B1 DERIVATIVES OF IMIDAZO [1,2-A]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI AVENTIS (FR) 2010-10-13 EP disclosed
US-7704989-B2 Derivatives of imidazo[1,2-a]pyridine-2-carboxamides, preparation method thereof and use of same in therapeutics SANOFI-AVENTIS (FR) 2010-04-27 US disclosed
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2009-06-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149441-A1 DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINE-2-CARBOXAMIDES, PREPARATION METHOD THEREOF AND USE OF SAME IN THERAPEUTICS NR4A2, NR4A3, NCOR1 RAB9A 3591/4885NPC1 1018/4885GAA 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.